PURPOSE. It has been known for nearly 50 years that cannabis and the psychoactive constituent D 9 -tetrahydrocannabinol (THC) reduce intraocular pressure (IOP). Elevated IOP remains the chief hallmark and therapeutic target for glaucoma, a major cause of blindness. THC likely acts via one of the known cannabinoid-related receptors (CB1, CB2, GPR18, GPR119, GPR55) but this has never been determined explicitly. Cannabidiol (CBD) is a second major constituent of cannabis that has been found to be without effect on IOP in most studies.
C
annabis has a long and storied history tracing back thousands of years. Only recently have we begun to understand how its constituents act in the body. D 9 -tetrahydrocannabinol (D 9 -THC, THC) is understood to be the chief psychoactive ingredient of cannabis. 1 The year 1971 marked the publication of the first work by Hepler and Frank 2 demonstrating that cannabis inhalation has a salutary effect on intraocular pressure (IOP). This set in motion a flurry of research to learn the nature of this effect. Remarkably, however, we still do not know through which receptors the principal components of cannabis regulate IOP. It is often assumed that THC does this via cannabinoid CB1 receptors, since CB1 receptor agonists lower IOP 3 but this has not been demonstrated. Ocular research into the two principal phytocannabinoids-THC and the noneuphoric cannabidiol (CBD)-largely ceased after the early 1980s, well before the first cannabinoid receptor was identified in 1990. 4 CB1 receptors remain the best-characterized cannabinoid receptor and are widely distributed in the brain 5 and eye 6 and regulate important physiological systems such as pain, mood, movement, and memory (for review see Ref. 7) . But the cannabinoid signaling system consists not only of CB1 receptors but also of CB2, 8 GPR18, 9 and GPR119 10 and perhaps others, as well as enzymes that produce and metabolize the lipid cannabinoid messengers (for review see Refs. 11 and 12) .
We have determined that at least three cannabinoid-related receptors (CB1, GPR18, GPR119) regulate IOP in the vertebrate eye. [13] [14] [15] Of these, THC activates CB1 and GPR18 16, 17 and perhaps GPR119. This means that the action of THC may be quite complex.
THC is not the only phytocannabinoid found in cannabis: CBD can be present at quantities comparable to THC and plant strains have now been developed (e.g., Charlotte's Web) that have a CBD to THC ratio that is heavily skewed toward CBD. Long considered inactive, CBD has shown benefit in clinical trials as an antiepileptic in Dravet's syndrome 18 and has recently been approved by the US Food and Drug Administration (FDA) as an antiepileptic. But CBD is also assigned many other properties, including activity at GPR18 19, 20 and the cannabinoid-metabolizing enzyme FAAH (fatty acid amide hydrolase), 21 but CBD may act as a negative allosteric modulator of CB1 signaling. 22, 23 This is significant because this means that CBD may antagonize THC signaling. Three of four studies that have tested CBD for effects on IOP have reported no effect, but the fourth has reported an increase in IOP. 24 The current study was an examination of the receptor dependence of the actions of THC and CBD on IOP.
the guidelines of the Indiana University animal care committee and in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice (male and female, age 3-8 months) were kept on a 12-hour (6:00 AM-6:00 PM) light/dark cycle, and fed ad libitum. Male and female mice were used for these experiments as noted and were obtained from the colony of Ken Mackie (Indiana University, Bloomington, IN, USA). Mice were C57BL/6J (C57) strain except CB 1 À/À mice, which were on a CD1 strain background. We have previously shown that mice on a CD1 background see reductions in ocular pressure upon topical treatment with CB1 cannabinoid agonists WIN55212 and CP55940, which are absent in CB1 knockouts.
14 Mice were allowed to acclimatize to the animal care facility for at least a week before their use in experiments. A total of 85 mice were used in these experiments. CB 1 À/À mice were kindly provided by Ken Mackie. The knockouts were global knockouts. CB 1 À/À animals were originally received from Catherine Ledent (Catholic University, Leuven) as heterozygotes. 25 
Intraocular Pressure Measurements
IOP was measured to test the effects of topically applied THC and CBD in living mice by rebound tonometry, using a Tonolab (Icare Finland Oy, Helsinki, Finland). To obtain reproducible IOP measurements, mice were anesthetized with isoflurane (3% induction). The anesthetized mouse was then placed on a platform in a prone position, where anesthesia was maintained with 2% isoflurane. Baseline IOP measurements were taken in both eyes. Measurements were initiated promptly (typically within a minute) after successful induction of anesthesia. Depth of anesthesia was assessed by paw press. A ''measurement'' consisted of the average value of six readings. One eye was then treated with drug (dissolved in Tocrisolve [Tocris Biosciences, Ellisville, MO, USA]), a soya-based solvent, 3 5 lL final volume, applied topically), while the other eye was treated with vehicle. Mice recover rapidly from isoflurane anesthesia. After an hour the animal was again anesthetized as above. IOP was then measured in the drug-treated and vehicletreated contralateral eye. This procedure (recovery from anesthesia, return to cage, reanesthetization, measurement of IOP) was repeated at the 4-and 8-hour time points as necessary.
IOP measurements following drug administration were analyzed by paired t-tests comparing drug-treated eyes to contralateral vehicle-treated eyes except for animals that had a time series (1, 4, and 8 hours), in which case a 2-way ANOVA with Bonferroni post hoc test was performed.
Quantitative RT-PCR
Primers for selected components of the endocannabinoid system were designed by using Primer-Blast (http://www.ncbi. nlm.nih.gov/tools/primer-blast, in the public domain) and the corresponding mouse gene. Primer sequences are as listed below: Eyes were extracted, the lens removed, and were then immediately stored at À808C. RNA was extracted with a Trizol reagent (Ambion, Austin, TX, USA) and genomic DNA was removed with DNase (NEB, Bethesda, MD, USA) following the manufacturer's instructions. RT-PCR was performed by using a one-step, Sybr Green amplification process (PwrSybr; Applied Biosystems, Carlsbad, CA, USA). Quantitative PCR was performed with an Eppendorf RealPlex2 Mastercycler thermocycler (Eppendorf, Hauppauge, NT, USA).
A primer for glyceraldehyde 3-phosphate dehydrogenase was used as an internal control for each experimental condition with the threshold cycle set within the linear range (10-fold above baseline). Once the standard critical threshold (Ct) was set, the relative expression levels for genes were determined.
Lipid Extraction and LC/MS/MS Analysis and Quantification
Enucleated eyes were flash frozen in liquid nitrogen and frozen at À808C until used for lipid analysis. Levels of~35 cannabinoid-related lipids as well as arachidonic acid and several prostaglandin-family metabolites were measured by liquid chromatography (LC)/mass spectrometry (MS) from whole eyes as previously described. 15, 26 Briefly, eyes were homogenized, centrifuged at 19,000g at 248C for 20 minutes and supernatant was collected. Compounds were isolated by using a partial purification of the 25% organic solution. C18 solid-phase extraction columns (Agilent Technologies, Santa Clara, CA, USA) were used with an elution of 100% methanol.
Samples were placed in an autosampler and held at 248C (Agilent 1100 series autosampler; Palo Alto, CA, USA) for LC/ MS/MS analysis. Ten to 20 lL of eluents were injected for each sample, which was rapidly separated with a C18 Zorbax reversed-phase analytic column (Agilent Technologies) to scan for individual compounds. Gradient elution (200 lL/min) then was accomplished under pressure (Shimadzu 10AdVP pumps; Shimadzu Scientific Instruments, Columbia, MD, USA). The electrospray ionization was done by using an API3000 triple quadrupole mass spectrometer (Applied Biosystems/DSM Sciex; Foster City, CA, USA). A multiple reaction monitoring (MRM) setting on the LC/MS/ MS was used to analyze levels of each compound. Synthetic standards were used to generate optimized MRM methods and standard curves for analysis.
Individual animals in each of the treatment groups were coded and experiments were analyzed in a blinded fashion. 
Materials

RESULTS
THC Lowers IOP in a Sex-Dependent Manner
We found that THC when applied topically (5 mM) lowered IOP relative to the vehicle-treated contralateral eye in male mice. This resultant drop in IOP was quite pronounced at 8 hours, with a nearly 30% drop in IOP (Fig. 1A , IOP in THC [5 mM]-treated versus vehicle-treated contralateral eye in males; 1 and 4 hours: n ¼ 7, 8 hours: n ¼ 8; *P < 0.05 by 1-way ANOVA with Bonferroni post hoc test versus contralateral eye at corresponding time point). Strikingly however, in female mice given the same treatment there was a more modest effect at 4 hours than the corresponding time point in males and no effect at 8 hours ( 
THC Lowers IOP Through Combined Activation of CB1 and GPR18 Receptors
As noted in the introduction, THC lowers IOP but the mechanism by which it does this remains undetermined. A preferred hypothesis is that THC lowers IOP via CB1 receptors. We therefore tested whether the effect of THC would be absent in CB1 receptor knockout mice. Interestingly, we found that CB1 deletion only partly eliminated the effect of THC ( Figs. 2A, 2B ; IOP in THC [5 mM]-treated versus vehicletreated contralateral eye in CB1 knockout (KO) males; 1 and 4 hours: n ¼ 12; *P < 0.05 by paired t-test versus contralateral eye at corresponding time point). This suggests that CB1 also acts via a second receptor. One likely candidate for this is the GPR18 receptor since, as noted previously, GPR18 can lower IOP in mice and is activated by THC. We therefore tested whether the GPR18 antagonist O-1918 (5 mM) applied topically to CB1 knockout mice would prevent the effect of THC. We found that there was no effect at 1 or 4 hours under this condition (Figs. 2C, 2D ; IOP in O1918 pretreated [5 mM topical] CB1 KOs: THC [5 mM]-treated versus vehicle-treated contralateral eye; 1 and 4 hours: n ¼ 5; *P < 0.05 by paired ttest versus contralateral eye at corresponding time point). This argues that THC lowers IOP through a combination of CB1 and GPR18.
CBD Has Two Independent Opposing Actions on IOP
As noted above, CBD has been tested in several studies for effects on IOP. Three of those studies found no effect, while the last saw an increase in IOP. CBD has been proposed to act on a large and growing number of receptors including recent evidence that CBD is a negative allosteric modulator at CB1 receptors. 23, 27 When tested in our model, we found that CBD (5 mM) in male mice substantially raised IOP at 1 and 4 hours (Figs. 3A, 3B ; IOP in CBD [5 mM]-treated versus vehicletreated contralateral eye in wild type (WT) males; 1 hour: n ¼ 13; 4 hours: n ¼ 19; *P < 0.05 by paired t-test versus contralateral eye at corresponding time point). Female mice saw a similar rise at both time points (data not shown). Strikingly, the same experiment in CB1 knockouts resulted in a decrease in ocular pressure at 1 hour but no effect at 4 hours (Figs. 3C, 3D ; IOP in CBD [5 mM]-treated versus vehicletreated contralateral eye in CB1 KO males; 1 and 4 hours: n ¼ 7; *P < 0.05 by paired t-test versus contralateral eye at corresponding time point). This indicates that CBD has two opposing effects on IOP. The first and dominant effect of raising IOP is likely CB1-dependent since the effect is absent in CB1 knockout mice and may be a consequence of cannabinoid receptor antagonism. We tested whether the IOP reduction was due to activity at GPR18 receptors, since GPR18 activation can lower IOP. 13 CBD had no effect on IOP in animals pretreated with the GPR18 antagonist O1918 (5 mM 
CBD Interferes With the IOP-Lowering Effects of THC
If CBD is raising pressure by acting as a negative allosteric modulator at CB1, then it is possible that coapplication of CBD and THC would cancel out the salutary effects of THC. To test this we treated mice (C57Bl/6J) with combined CBD/THC (5 mM/5 mM) and found that there was no effect on IOP relative to vehicle (Fig. 4 , IOP in THC and CBD [5 mM each]-treated versus vehicle-treated contralateral eye in WT males; 1 and 4 hours: n ¼ 7; NS by paired t-test versus contralateral eye at corresponding time point).
mRNA Levels for CB1 and GPR18 Are Higher in Eyes of Male Than Female Mice
If there is a sex dependence in the effect of THC, what is the basis of that difference? Are there fewer CB1 receptors, or GPR18 receptors, or both? One way to test this is to examine the mRNA expression of these receptors in the eyes of male versus female mice. We examined mRNA expression for CB1 and GPR18 by using quantitative PCR, finding that mRNA levels of CB1 and GPR18 were lower in female mice than male mice ( Fig. 5 ; n ¼ 9 per condition; *P < 0.05 unpaired t-test male versus female).
Cannabinoid-Related Lipid Species Are Elevated After CBD Treatment
Though the IOP-lowering effect is blocked by a GPR18 antagonist, the action of CBD may be direct or indirect, particularly since, as noted previously, CBD has been shown to act at the endocannabinoid-metabolizing enzyme FAAH. To explore this we measured levels of~35 cannabinoid-related lipids as well as several prostaglandins and related lipids 1 hour after treatment with CBD. In a given animal, one eye received CBD while the contralateral eye received vehicle (N ¼ 6). As shown in the Table, the levels of most acylethanolamines rose, though not arachidonoyl-ethanolamine (AEA), an endogenous ligand for CB1/CB2 receptors. Levels of two N-acyl-gammaaminobutyric acid (GABA) and N-acyl-taurine species were elevated. Intriguingly, levels of the GPR18 ligand N-oleoylglycine (NOGly) and the GPR119 ligand 2-oleoylglycerol were also elevated.
DISCUSSION
Nearly half a century after reports of a salutary effect of cannabinoids on ocular pressure we still do not know the mechanism by which this occurs. Our chief findings in normotensive mice were that THC lowers pressure substantially and for at least 8 hours, through a combined action at two receptors, CB1 and GPR18. This effect was sex-dependent, with much stronger responses in male mice. CBD in contrast had two opposing actions on IOP: raising IOP in wild-type animals but lowering it in CB1 knockout mice likely via GPR18. Finally, at equal concentrations CBD prevented the IOPlowering effects of THC.
Sex-dependent effects have been reported for cannabis (e.g., in the study by Cooper and Haney 28 ) but sex dependence had not been explored for cannabinoid regulation of IOP. Phytocannabinoids are not currently considered a suitable firstline therapeutic for glaucoma (e.g., American Academy of Ophthalmology [AAO] position statement 2014, www.aao. org); however, this may be based on limited evidence. The central argument is that topical THC is not effective, therefore necessitating treatment via cannabis inhalation. Cannabis inhalation, in turn, has assorted shortcomings: (1) psychoactivity, (2) short action (<4 hours), and (3) elevation of blood pressure. A key question then is whether topical THC works in humans. The negative conclusion is based on four studies, three of which pool male and female subjects. In the two 1981 studies by Merritt et al., 29, 30 most subjects are female (4/6, 7/ 8). Green and Roth 31 (1982) do not specify the makeup of their subject pool but exclude pregnant subjects, implying the presence of females, leaving only one study that includes only males. 32 The sex dependence of THC regulation of IOP, with the robust effects in males that we report here, combined with topical THC studies in animals (e.g., Merritt et al., 29 Green et al., 33 ElSohly et al., 34 ), suggests that the question of topical THC as a means to lower ocular pressure may merit some reconsideration.
It is notable that no less than three cannabinoid related receptors, namely, CB1, GPR18, and GPR119, each lower IOP when activated. Moreover, they all exhibit sex dependence, but differentially. mRNA expression of CB1 and GPR18 is elevated in male mice relative to female mice. It must be noted that differential mRNA expression does not necessarily correspond to protein levels (e.g., Western blot). However the difference in mRNA is consistent with our finding that dual activation of these receptors by THC yields a stronger effect in males. In contrast, the X-linked GPR119 receptor lowers IOP preferentially in female mice. 15 Our results also raise the possibility that the diurnal variation of IOP, in which GPR18 plays a role, 35 is sex-dependent. The elevation of IOP by CBD is consistent with CB1 antagonism. If CBD truly interferes with the actions of THC then low-CBD strains may offer superior results for studies involving cannabis inhalation. The second mechanism of action for CBD-the one that underlies IOP-reduction-may be due to direct or indirect activity at GPR18, since there is no effect on IOP by CBD if GPR18 and CB1 are both blocked/deleted. As noted above, CBD has been shown to be active at GPR18 19, 20 and may block FAAH, 21 which could also elevate acylethanolamines, as we have recently shown, 35 including AEA, a precursor for GPR18 ligand NAGly. 9 Our lipidomic analysis revealed rises in several cannabinoid-related lipids. Levels of GPR18 ligand NAGly were not elevated but we did see a rise in the closely related NOGly, which may also activate GPR18 (data not shown). This may account for the observed GPR18-dependent effects. Levels of four of the six acylethanolamines tested were seen to rise after CBD treatment. Interestingly, of these, oleoylethanolamide (OEA) and palmitoylethanolamide have been shown by Syed et al. 36 to activate GPR119, which can also lower ocular pressure in female-but not male-mice when activated. 15 Moreover, levels of 2-oleoylglycerol, a GPR119 ligand that also lowers IOP, 15 were also seen to rise and may contribute to the signaling profile of CBD.
One consideration in interpreting the duration of effects of THC and CBD relates to rates of metabolism and clearance. We did not assess the pharmacokinetics of these compounds. Since they are structurally quite similar (with identical molecular weight), it is unlikely that one of the original compounds is removed much more rapidly than the other. However, while the hepatic metabolism of these compounds has been studied extensively, potential metabolism in the eye is unstudied. In principle, the apparent temporal difference between CBD and THC effects in the eye may be a function of differential ocular metabolism. In principle CBD and THC may also impact each other's metabolism, the so-called entourage effect. Competition for enzymatic breakdown is generally hypothesized to enhance the signaling of THC, whereas we saw a diminished response, but it is difficult to ascertain without further, explicit study of THC/CBD pharmacokinetics in the eye.
It is valuable to understand the mechanisms by which THC and CBD regulate intraocular pressure, particularly at a time when their changing legal status and the perception of phytocannabinoids as safe contribute to a continued growth in their availability and popular embrace. CBD in particular has recently been approved by the FDA as an antiepileptic and is available in many grocery stores. We find that the regulation of ocular pressure by THC and CBD is more complex than previously appreciated. THC acts via a combination of CB1 and GPR18 receptors in a sex-dependent manner, while CBD can both raise IOP and interfere with the effects of THC. The potential of CBD to elevate ocular pressure should be evaluated further as a potential deleterious side effect, particularly with long-term use. Our finding of sex dependence of cannabinoid regulation of ocular pressure suggests that the current academic view that topical phytocannabinoids are without effect (e.g., the 2014 AAO position statement on cannabis and glaucoma) may be premature. Most of the studies Table shows lipids for which analytic standards were included for analysis. Nine of these were below detectable levels. denotes 3-to 9.99-fold increase; denotes 2-to 2.99-fold increase; denotes 1.50-to 1.99-fold increase; denotes 1-to 1.49-fold increase. BAL, below analytic limits; LEA, linoleoyl ethanolamie; NAE, N-arachidonoyl ethanolamine; PG, prostaglandin.
on which this position is based include female subjects but are underpowered to evaluate a potential sex dependence of effect. However, it should be stressed that the findings presented here highlight the complex endogenous cannabinoid signaling system that can be selectively targeted and harnessed to lower ocular pressure by other means. For instance, we have shown that it is possible to enhance endogenous cannabinoid signaling by blocking the cannabinoid-metabolizing enzyme monoacylglycerol lipase 37 and so lower ocular pressure. Similarly, we have found that activating CB1 directly 38 can achieve the same outcome. Our findings for THC suggest that a dual CB1/GPR18 agonist may prove advantageous. The study of phytocannabinoids such as THC and CBD, but also others derived from the plant, may therefore point to novel strategies to promote ocular health.
